Abbott Laboratories

Abbott Laboratories

ABTยทNYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Mรฉniรจre's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026
Abbott Laboratories

Abbott Laboratories Fair Value Envelope

ABT ยท NYSE

Our analysis suggests that ABT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $87.02, this represents a potential HIDDEN relative to our calculated worth for Abbott Laboratories.

Intrinsic Value
Current Price: $87.02

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$470.8B
+ Cash & Equivalents$8.5B
Firm Value$479.3B
- Debt$15.1B
Equity Value$464.2B
/ Shares Outstanding1,740,561,287B
DCF Value$267
UNDERVALUED BY 206%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$11.1B
$13.0B
$15.1B
$17.6B
$20.5B
$23.8B
$27.8B
$32.3B
$37.6B
$43.8B
Maintenance CapEx
-$505.6M
-$588.7M
-$685.5M
-$798.1M
-$929.3M
-$1.1B
-$1.3B
-$1.5B
-$1.7B
-$2.0B
Owner Earnings
$10.6B
$12.4B
$14.4B
$16.8B
$19.5B
$22.8B
$26.5B
$30.9B
$35.9B
$41.8B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$9.8B
$10.6B
$11.4B
$12.3B
$13.3B
$14.3B
$15.5B
$16.7B
$18.0B
$19.4B
Terminal Value represents 70.0% of Enterprise Value